Calcinosis Reduction by Pyrophosphate in SSC

Launched by SZEGED UNIVERSITY · Jul 16, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating whether a medication called pyrophosphate, taken by mouth, can help prevent the formation of calcinosis in patients with systemic sclerosis (also known as scleroderma). Calcinosis involves the development of painful, crystal-like lumps under the skin, which can be a challenging complication of this autoimmune disease. The researchers want to see if pyrophosphate can reduce or stop these lumps from forming.

To participate in the trial, individuals need to be between the ages of 18 and 75 and must meet specific classification criteria for systemic sclerosis. However, those with severe symptoms affecting their upper body, thyroid issues, or certain heart conditions may not be eligible. The trial is currently not recruiting participants, but once it starts, volunteers can expect to take the medication and be monitored by the research team to assess its effects on calcinosis. This study could be an important step in finding new ways to manage this painful complication of systemic sclerosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • to meet ACR/ EULAR classification criteria
• Exclusion Criteria:
• • severe upper minfestation of SSC
• • hypo- or hyperthyreoidism
• • QT prolongation on ECG